Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

The standard treatment for patients with acute myeloid leukemia (AML) with an abnormality in the IDH1 gene, who are not eligible for intensive chemotherapy, is a combination of ivosidenib and azacitidine. In this study it is investigated whether adding venetoclax to the standard treatment can improve the outcome of the treatment of this specific form of AML. The safety is investigated and how well it works. In order to properly assess the value of venetoclax, the effect of venetoclax is compared with the effect of a placebo. A placebo is a product without an active ingredient, a 'fake medicina

Trial Details

NCT ID
NCT07075016
Phase
PHASE3
Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Venetoclax 400
  • Placebo
Locations (sample)
  • Feldkirch, Austria|47.23645,9.59734
  • Salzburg, Austria|47.79941,13.04399
  • Vienna, Austria|48.20849,16.37208
  • Antwerp, Belgium|51.22047,4.40026
  • Brussels, Belgium|50.85045,4.34878

Key Eligibility Criteria

  • Patient with newly diagnosed IDH1-mutated AML, or IDH1-mutated MDS/AML according to the 2022 International Consensus Classification (Appendix A). P…
  • Central confirmation of IDH1 mutation in one of the dedicated central genetic laboratories.
  • Age ≥ 18 years, no upper age limit.
  • Patient is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →